库马林杂交物:未来抗微生物和抗结核疗法的双重目标候选者
Abhay Bavishi1, Hardev Vala2, Shailesh Thakrar1
1Department of Chemistry, Christ College, Rajkot, India.
Future medicinal chemistry
|May 12, 2025
概括
新型库马林衍生物显示出作为双重向抗菌剂的前景. 9系列的化合物对细菌和Mycobacterium结核病具有显著的活性,具有药物开发的潜力.
科学领域:
- 药用化学 医学化学
- 有机合成 有机合成
- 抗菌研究 抗菌研究
背景情况:
- 库马林衍生物被认为具有多种生物活性.
- 开发新型抗菌剂对于对抗日益增长的耐药性至关重要.
- 针对多种细菌酶提供了一种克服抗药机制的策略.
研究的目的:
- 合成和描述基于库马林的新型衍生物 (5系列和9系列).
- 评估这些化合物的抗微生物和抗结核活性.
- 研究结构-活性关系 (SAR) 和与关键细菌点的分子相互作用.
主要方法:
- 库马林衍生物的合成和光谱表征.
- 在体外抗微生物和抗结核活性测定 (IC50测定).
- 针对Mycobacterium结核病基-ACP减少酶 (InhA) 和大肠杆菌DNA旋转酶B的分子对接研究.
主要成果:
- 第5系列的化合物显示出中度的抗菌活性.
- 9系列的衍生品表现出强大的双重向抑制对抗格拉姆阳性细菌.
- 化合物9c对Mycobacterium tuberculosis (1.50μg/mL) 的IC50显示为最低,而化合物9a和9b也显示出显著的活性.
- 分子对接结果与观察到的生物活动相关,表明强大的结合相互作用.
结论:
- 系列9库马林衍生物,特别是9t,9c和9a,显示出作为双重向抗菌药物候选药物的巨大潜力.
- 这些化合物需要进一步研究和优化治疗应用.
- 这项研究强调了库马林衍生物的SAR及其与重要细菌酶的相互作用.
相关概念视频
Combined Effects of Drugs: Synergism
3.6K
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
Such synergistic combinations...
3.6K
Pulmonary Tuberculosis V
155
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
155
Targets for Drug Action: Overview
5.9K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
5.9K
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.0K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.0K
Anticoagulant Drugs: Low-Molecular-Weight Heparins
546
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
546
Drugs that Stabilize Microtubules
1.9K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
1.9K


